Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,611.69
(
0.84%
)
US TECH 100
23,604.60
(
1.05%
)
Dow Jones
46,480.99
(
0.77%
)
Brent Oil
96.84
(
0.35%
)
Bitcoin
71,381.00
(
1.22%
)
News Focus
News Focus
Post# of 257282
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122810
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oc631 post# 121247

Wednesday, 06/22/2011 5:59:49 AM

Wednesday, June 22, 2011 5:59:49 AM

Post# of 257282
JNJ/Medivir start phase-1b trial of HCV nuke, TMC649128:

http://finance.yahoo.com/news/Medivir-TMC649128-enters-bw-3338105057.html?x=0&.v=1

It is anticipated that TMC649128 will be used in combination with other HCV direct acting antiviral agents, given its high genetic barrier to resistance and antiviral activity across multiple HCV genotypes.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now